☰
✕
Home/ Healthcare/ Europe Obesity Treatment Market
Request for TOC Request for Sample
BUY NOW

Europe Obesity Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Healthcare | Published Report | Apr 2025 | Europe | 350 Pages | No of Tables: 235 | No of Figures: 37
Buy Now Request for Sample
Nucleus

Circumvent the Tariff challenges with an agile supply chain Consulting

Supply Chain Ecosystem Analysis now part of DBMR Reports

Europe Obesity Treatment Market

Market Size in USD Billion

CAGR :  %

USD 7.48 Million USD 21.38 Million 2024 2032
Forecast Period
 2025 –2032
Market Size(Base Year)
USD 7.48 Million
Market Size (Forecast Year)
 USD 21.38 Million
CAGR
 %
Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
Request For Unlock

Europe Obesity Treatment Market Segmentation, By Treatment Type (Pharmacological Treatments (Anti-obesity Drugs), Bariatric Surgery, Behavioral & Lifestyle Therapy, Non-Invasive/ Endoscopic Procedures, and Medical Devices & Technologies), Age Group (Adult Obesity Treatment, Geriatric Obesity Treatment, and Pediatric Obesity Treatment), Distribution Channel (Online Pharmacies, Retail Pharmacies, Weight Management Clinics, Hospital Pharmacies, and Wellness & Fitness Centers), Patient Type (Class III, Class II, and Class I) - Industry Trends and Forecast to 2032

Get Exclusive Sample Copy of this Report Here

Europe Obesity Treatment Market Size

  • The Europe Obesity Treatment Market was valued at USD  7.48 Million in 2024 and is expected to reach USD 21.38 Million by 2032

  • During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 14.0% primarily driven by the increasing prevalence of obesity

  • This growth is driven by factors such as innovations in anti-obesity medications, growth in bariatric and metabolic surgeries. In addition, integration of digital health solutions in obesity treatment

Europe Obesity Treatment Market Analysis

  • Obesity is a chronic medical condition characterized by excessive fat accumulation, increasing the risk of severe health complications such as cardiovascular diseases, type 2 diabetes, hypertension, and certain cancers

  • Treatment options range from lifestyle modifications, pharmacotherapy, and medical devices to bariatric surgery, aiming to achieve sustainable weight loss and improve overall health outcomes

  • The Europe obesity treatment market is driven by the rising prevalence of obesity due to sedentary lifestyles, unhealthy dietary habits, and genetic predisposition. Pharmacological interventions, including GLP-1 receptor agonists and appetite suppressants, play a crucial role in weight management, alongside behavioral therapy and lifestyle changes. Bariatric surgeries, such as gastric bypass and sleeve gastrectomy, are also gaining traction as effective long-term solutions for severe obesity

  • The increasing demand for minimally invasive procedures and innovative anti-obesity medications is further propelling market growth

  • North America remains a dominant region in the Europe obesity treatment market, supported by well-established healthcare infrastructure, high obesity rates, and continuous research in weight management solutions

  • For instance, the U.S. leads in the adoption of GLP-1 receptor agonists like semaglutide and liraglutide, along with advancements in non-invasive medical devices designed for weight loss

  • With a growing emphasis on obesity management and preventive healthcare, the Europe market is witnessing significant investments in novel therapies, medical technologies, and patient-centric solutions, driving overall industry expansion

Report Scope and Obesity Treatment Market Segmentation  

Attributes

Europe Obesity Treatment Market Key Market Insights

Segments Covered

  • By Treatment Type- Pharmacological Treatments (Anti-obesity Drugs), Bariatric Surgery, Behavioral & Lifestyle Therapy, Non-Invasive/ Endoscopic Procedures, and Medical Devices & Technologies

  • By Age Group -Adult Obesity Treatment, Geriatric Obesity Treatment, and Pediatric Obesity Treatment

  • By Distribution Channel- Online Pharmacies, Retail Pharmacies, Weight Management Clinics, Hospital Pharmacies, and Wellness & Fitness Centers.

  • By Patient Type -Class III, Class II, and Class I

Countries Covered

Europe

  • Germany

  • U.K.

  • France

  • Russia

  • Italy

  • Spain

  • Turkey

  • Poland

  • Netherlands

  • Switzerland

  • Norway

  • Austria

  • Ireland

  • Rest of Europe

Key Market Players

  • Novo Nordisk A/S (Denmark)

  • Eli Lilly and Company (U.S.)

  • Medtronic (U.S.)

  • Boston Scientific Corporation (U.S.)

  • Johnson & Johnson Services, Inc. (U.S.)

  • Altimmune (U.S.)

  • AstraZeneca (UK)

  • Allurion (U.S.)

  • Amgen Inc. (U.S.)

  • Arena Pharmaceuticals Ltd (U.S.)

  • Currax pharmaceuticals LLC (U.S.)

  • COUSIN SURGERY (France)

  • F. Hoffmann-La Roche Ltd (Switzerland)

  • Fitterfly Healthtech Pvt. Ltd. (India)

  • Morphic Medical, Inc (U.S.)

  • Noom, Inc. (U.S.)

  • Omada Health Inc (U.S.)

  • Reshape Lifesciences Inc. (U.S.)

  • Raziel (Isarel)

  • Spatz FGIA Inc. (U.S.)

  • Sanofi (France)

  • Saniona (Denmark)

  • USGI Medical (U.S.)

  • VIVUS LLC. (U.S.)

  • Viking Therapeutics (U.S.)

Market Opportunities

  • Increasing prevalence of lifestyle related diseases

  • Rising disposable income enhancing the purchasing power for obesity treatment related products

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Europe Obesity Treatment Market Trends

Rising Adoption of Digital and AI-Driven Weight Management Solutions

  • A key trend in the Europe obesity treatment market is the increasing adoption of digital and AI-driven weight management solutions

  • These innovative technologies enhance obesity management by providing personalized treatment plans, real-time monitoring, and data-driven insights to optimize weight loss strategies

    • For instance, AI-powered mobile applications and wearable devices track physical activity, caloric intake, and metabolic rates, offering tailored recommendations to improve adherence and outcomes

  • Telemedicine platforms and virtual coaching further support patients by providing remote consultations, behavioral counseling, and medication management, leading to more effective and sustainable weight loss

  • This trend is revolutionizing obesity care by improving patient engagement, enhancing long-term treatment success, and driving demand for digital health solutions in the obesity treatment market

Europe Obesity Treatment Market Dynamics

Driver

Increasing Prevalence of Obesity

  • The obesity epidemic is escalating due to sedentary lifestyles, poor dietary habits, and genetic predisposition, leading to a sharp increase in obesity-related health complications such as diabetes, cardiovascular diseases, and hypertension

  • Urbanization and technological advancements have contributed to reduced physical activity, while widespread consumption of processed and high-calorie foods has further fueled weight gain

  • Genetic factors also play a significant role, with many individuals being predisposed to metabolic disorders that contribute to obesity. As obesity rates continue to surge, the demand for effective treatment solutions, including pharmacological therapies, bariatric surgeries, and medically supervised weight management programs, is rising significantly

For instance

  • In March 2024, as per the information provided by WHO, the Europe obesity epidemic is escalating, with 1 in 8 people living with obesity in 2022. Adult obesity has doubled since 1990, and adolescent obesity has quadrupled. Over 2.5 billion adults were overweight, including 890 million with obesity. Rising obesity rates contribute to increased risks of diabetes, heart disease, and cancer, fueling demand for effective treatments and driving market growth

  • In September 2024, as highlighted by the Centers for Disease Control and Prevention, between August 2021 and August 2023, 40.3% of adults were living with obesity, with 39.2% of men and 41.3% of women affected. The highest prevalence was among adults aged 40–59 (46.4%), followed by 20–39 (35.5%) and 60+ (38.9%). The increasing obesity burden is expected to drive demand for effective obesity treatments

  • In 2024, as mentioned by World Obesity Atlas, by 2035, 79% of overweight and obese adults and 88% of overweight and obese children will reside in Low- and Middle-Income Countries (LMICs). The number of adults with obesity is projected to increase from 0.81 billion in 2020 to 1.53 billion in 2035. This rising prevalence is increasing the demand for obesity treatment solutions, driving market growth

  • This growing patient burden is driving healthcare providers, pharmaceutical companies, and wellness programs to expand their offerings, making the rising prevalence of obesity a key driver for the Europe obesity treatment market

Opportunity

Increasing Prevalence of Lifestyle Related Diseases

  • As more individuals seek to manage their weight and mitigate associated health risks, pharmaceutical companies and healthcare providers are incentivized to innovate and expand their offerings

  • This trend fosters the development of new medications, surgical options, and comprehensive lifestyle programs tailored to diverse patient needs

For instance

  • In May 2023, NCBI stated that it is estimated that more than 1 billion people will be living with obesity by 2030.1 The higher rates of obesity-associated mortality and comorbidities, such as diabetes, cardiovascular disease, chronic kidney disease, and several types of cancer, are equally staggering, with an average of 5 million deaths and 160 million disability-adjusted life-years

  • In June 2023, according to an article published by Acta Pharmaceutica Sinica B, obesity strongly contributes to the development of cancer, cardiovascular diseases, type 2 diabetes, liver diseases and other disorders

  • In April 2021, according to an article published in the American Heart Association Journals, Obesity contributes directly to incident cardiovascular risk factors, including dyslipidemia, type 2 diabetes, hypertension, and sleep disorders. Obesity also leads to the development of cardiovascular disease and cardiovascular disease mortality independently of other cardiovascular risk factors

  • In April 2023, a study by MoneyControl outlined that India has experienced a massive spike in lifestyle diseases, including an increase in the prevalence of early risk factors like obesity and cholesterol irregularities

  • In addition, heightened awareness regarding the health consequences of obesity encourages proactive health management among consumers. With supportive initiatives from governments and health organizations promoting healthier lifestyles, the obesity treatment market is poised for substantial growth

  • This momentum attracts investment and boosts research and development efforts, paving the way for a wide range of therapeutic interventions to meet the needs of an expanding patient population

Restraint/Challenge

Long-Term Follow-Ups Associated With Obesity Treatment

  • Long-term follow-ups associated with obesity treatment primarily due to the complexity and resource intensiveness of such programs often requires continuous monitoring and support to ensure sustained weight loss and management, which can include regular consultations, nutritional guidance, and behavioral therapy

  • These long-term commitments burden healthcare systems and pose logistical challenges for both patients and providers, leading to potential gaps in care and inconsistent treatment adherence

For instance

  • In December 2022, as per AJMC, managing obesity requires the ongoing partnership of a committed patient and informed clinicians. Managing obesity requires the ongoing partnership of a committed patient and informed clinicians

  • In September 2022, JAMA Network reported that, in research carried for 175 patients, 94 (53.7%) had weight loss of at least 5% and 26 (14.9%) had weight loss of 10% or more at 3 months. Of 102 patients who were followed up for 6 months, 89 (87.3%) achieved weight loss of 5% or more, 56 (54.9%) achieved weight loss of 10% or more, 24 (23.5%) achieved weight loss of 15% or more, and 8 (7.8%) achieved weight loss of 20% or more

  • In November 2021, according to an article published by the National Library of Medicine, ensuring a long-term follow-up seems to be of the utmost importance for bariatric patients. Low quality follow-up in bariatric surgery is indicated as a risk factor for poor outcomes but the versatility and effectiveness of follow-up are also determinants of clinical research

  • Moreover, the necessity for long-term follow-ups deters individuals from seeking treatment initially. Many prospective patients may be apprehensive about the ongoing commitment and costs associated with regular check-ins and monitoring, which is perceived as daunting or inconvenient

  • This hesitancy impedes market growth, as potential consumers shy away from programs that require sustained engagement and accountability

  • Consequently, the challenge of facilitating effective long-term follow-ups may limit the overall effectiveness of obesity treatments and their acceptance among the target population

Europe Obesity Treatment Market Scope

The market is segmented on the basis of type, product type, absorption site, age group, source, delivery method, gender, and distribution channel.

Segmentation

Sub-Segmentation

  • Treatment Type

  • Pharmacological Treatments (Anti-obesity Drugs)

    • GLP-1 Receptor Agonists

    • Dual GIP/ GLP-1 Receptor Agonists

    • Centrally Acting Anorectics

      • Phentermine

      • Phentermine-Topiramate

      • Naltrexone-Bupropion

    • Lipase Inhibitors

    • Deoxycholic Acid

    • Others

  • Bariatric Surgery

  • By Type

    • Restrictive Surgeries

      • Sleeve gastrectomy

      • Adjustable gastric banding

    • Combination Surgeries

      • Roux-en-Y gastric bypass (RYGB)

      • Mini-gastric bypass (MGB)

    • Malabsorptive Surgeries

  • By Approach

    • Laparoscopic Surgery

    • Robotic-Assisted Surgery

    • Open Surgery

  • Behavioral & Lifestyle Therapy

    • Dietary Interventions

    • Behavioral Modification Therapy

    • Physical Activity Programs

    • Psychological Counseling

  • Non-Invasive/ Endoscopic Procedures

    • Endoscopic Sleeve Gastroplasty (ESG)

    • Intragastric Balloon (IGB)

      • Orbera intragastric balloon

      • Spatz adjustable balloon system

    • Aspiration Therapy (AspireAssist)

    • Transoral Gastroplasty (TOGA)

  • Medical Devices & Technologies

      • Artificial Intelligence & Digital Weight Management Platforms

      • Gastric Electrical Stimulation Devices (Maestro System)

  • Age Group

  • Adult Obesity Treatment

  • Geriatric Obesity Treatment

  • Pediatric Obesity Treatment

  • Distribution Channel-

  • Online Pharmacies

  • Retail Pharmacies

  • Weight Management Clinics

  • Hospital Pharmacies

  • Wellness & Fitness Centers

  • Patient Type

  • Class III

  • Class II

  • Class I

Europe obesity treatment market Regional Analysis

Germany is the Dominant Region in the Insulin Market for Type 1 and Type 2 Diabetes

  • Germany  leads the Europe obesity treatment market, driven by a high prevalence of obesity, advanced healthcare infrastructure, and strong adoption of innovative weight management solutions

  • The Germany holds a significant market share due to the rising demand for pharmacological treatments like GLP-1 receptor agonists, bariatric surgeries, and digital weight management platforms

  • In addition, increasing awareness about obesity-related health risks and the growing adoption of AI-driven weight loss programs, telehealth consultations, and non-invasive treatment solutions continue to fuel market expansion in the region

Poland is Projected to Register the Highest Growth Rate

  • The Poland region is expected to witness the highest growth rate in the Europe obesity treatment market, driven by increasing obesity prevalence, rising healthcare investments, and growing awareness about weight management solutions.

  • Countries such as Poland, Russia, and Romania are emerging as key markets due to shifting lifestyle patterns, rising urbanization, and an increasing number of obesity-related health complications.

  • Poland, with its expanding healthcare infrastructure and growing demand for medical weight loss treatments, remains a crucial market for obesity management. The country is witnessing increased adoption of pharmacological treatments, bariatric surgeries, and digital weight management programs.

Europe Obesity Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

  • Novo Nordisk A/S (Denmark)

  • Eli Lilly and Company (U.S.)

  • Medtronic (U.S.)

  • Boston Scientific Corporation (U.S.)

  • Johnson & Johnson Services, Inc. (U.S.)

  • Altimmune (U.S.)

  • AstraZeneca (UK)

  • Allurion (U.S.)

  • Amgen Inc. (U.S.)

  • Arena Pharmaceuticals Ltd (U.S.)

  • Currax pharmaceuticals LLC (U.S.)

  • COUSIN SURGERY (France)

  • F. Hoffmann-La Roche Ltd (Switzerland)

  • Fitterfly Healthtech Pvt. Ltd. (India)

  • Morphic Medical, Inc (U.S.)

  • Noom, Inc. (U.S.)

  • Omada Health Inc (U.S.)

  • Reshape Lifesciences Inc. (U.S.)

  • Raziel (Isarel)

  • Spatz FGIA Inc. (U.S.)

  • Sanofi (France)

  • Saniona (Denmark)

  • USGI Medical (U.S.)

  • VIVUS LLC. (U.S.)

  • Viking Therapeutics (U.S.)

Latest Developments in Europe Obesity Treatment Market

  • In October 2024, VIVUS and UpScriptHealth have launched ChooseQ. online, a telehealth platform that offers convenient access to QSYMIA for weight management. This service allows patients to consult with healthcare providers online and receive QSYMIA directly at home. This initiative aims to improve accessibility to obesity treatment through telemedicine

  • In October 2024, Zealand Pharma announced that Boehringer Ingelheim received U.S. FDA Breakthrough Therapy designation for Survodutide (BI 456906) for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate or advanced fibrosis. This designation accelerates its development due to promising Phase II results

  • In March 2025, Zealand Pharma announced the completion of participant enrolment in the Phase 2b ZUPREME-1 trial for Petrelintide, a long-acting amylin analog aimed at treating overweight and obesity. The trial will assess the effects of various doses of Petrelintide on body weight, safety, and tolerability over 42 weeks, with results expected in 2025

  • On March 2025, Raziel Therapeutics, a pharmaceutical company focused on next-generation prescription products for the medical aesthetics market, has announced the initiation of a Phase 3 clinical study in China for RZL-012, aimed at reducing submental fat (SMF). SMF reduction is the first indication for RZL-012, with potential applications for various aesthetic fat reduction treatments in body shaping

  • In October 2022, ReShape Lifesciences, a leader in weight loss and metabolic health solutions, announced that the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) have released updated guidelines for Metabolic and Bariatric Surgery, which now include the Lap-Band. These guidelines replace the previous 30-year-old standards established by the National Institutes of Health (NIH) in 1991

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE EUROPE OBESITY TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 MULTIVARIATE MODELLING

2.6 TREATMENT TYPE LIFELINE CURVE

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 EPIDEMIOLOGY: EUROPE OBESITY TREATMENT MARKET

4.4 DRUG TREATMENT RATE BY MATURED MARKETS: EUROPE OBESITY TREATMENT MARKET

4.5 DRUG

4.6 WORD PIPELINE

5 REGULATORY FRAMEWORK FOR THE EUROPE OBESITY TREATMENT MARKET

5.1 REGULATORY APPROVAL PATHWAYS

5.2 LICENSING AND REGISTRATION

5.3 REGULATORY APPROVAL PATHWAYS

5.4 LICENSING AND REGISTRATION

5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF OBESITY

6.1.2 INNOVATIONS IN ANTI-OBESITY MEDICATIONS

6.1.3 GROWTH IN BARIATRIC AND METABOLIC SURGERIES.

6.1.4 INTEGRATION OF DIGITAL HEALTH SOLUTIONS IN OBESITY TREATMENT

6.2 RESTRAINTS

6.2.1 ANTI-OBESITY DRUGS AND SURGICAL INTERVENTIONS CARRY RISKS

6.2.2 HIGH RELAPSE RATES POST-TREATMENT OF OBESITY

6.3 OPPORTUNITIES

6.3.1 INCREASING PREVALENCE OF LIFESTYLE RELATED DISEASES

6.3.2 RISING DISPOSABLE INCOME ENHANCING THE PURCHASING POWER FOR OBESITY TREATMENT RELATED PRODUCTS

6.3.3 RISE IN STRATEGIC INITIATIVES AND LAUNCHES BY MARKET PLAYERS

6.4 CHALLENGES

6.4.1 LONG-TERM FOLLOW-UPS ASSOCIATED WITH OBESITY TREATMENT

6.4.2 ADDRESSAL OF THE LIFESTYLE AND BEHAVIORAL CHANGES

7 EUROPE OBESITY TREATMENT MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS)

7.2.1 GLP-1 RECEPTOR AGONISTS

7.2.2 DUAL GIP/ GLP-1 RECEPTOR AGONISTS

7.2.2.1 Phentermine

7.2.2.2 Phentermine-Topiramate

7.2.2.3 Naltrexone-Bupropion

7.2.3 LIPASE INHIBITORS

7.2.4 DEOXYCHOLIC ACID

7.2.5 OTHERS

7.3 BARIATRIC SURGERY

7.3.1 RESTRICTIVE SURGERIES

7.3.1.1 Sleeve gastrectomy

7.3.1.2 Adjustable gastric banding

7.3.2 COMBINATION SURGERIES

7.3.2.1 Roux-en-Y gastric bypass (RYGB)

7.3.2.2 Mini-gastric bypass (MGB)

7.3.3 MALABSORPTIVE SURGERIES

7.3.3.1 Laparoscopic Surgery

7.3.3.2 Robotic-Assisted Surgery

7.3.3.3 Open Surgery

7.4 BEHAVIORAL & LIFESTYLE THERAPY

7.4.1 DIETARY INTERVENTIONS

7.4.2 BEHAVIORAL MODIFICATION THERAPY

7.4.3 PHYSICAL ACTIVITY PROGRAMS

7.4.4 PSYCHOLOGICAL COUNSELING

7.5 NON-INVASIVE/ ENDOSCOPIC PROCEDURES

7.5.1 ENDOSCOPIC SLEEVE GASTROPLASTY (ESG)

7.5.2 INTRAGASTRIC BALLOON (IGB)

7.5.2.1 Orbera intragastric balloon

7.5.2.2 Spatz adjustable balloon system

7.5.3 ASPIRATION THERAPY (ASPIREASSIST)

7.5.4 TRANSORAL GASTROPLASTY (TOGA)

7.6 MEDICAL DEVICES & TECHNOLOGIES

7.6.1 ARTIFICIAL INTELLIGENCE & DIGITAL WEIGHT MANAGEMENT PLATFORMS

7.6.2 GASTRIC ELECTRICAL STIMULATION DEVICES (MAESTRO SYSTEM)

8 EUROPE OBESITY TREATMENT MARKET, BY AGE GROUP

8.1 OVERVIEW

8.2 ADULT OBESITY TREATMENT

8.3 GERIATRIC OBESITY TREATMENT

8.4 PEDIATRIC OBESITY TREATMENT

9 EUROPE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW

9.2 ONLINE PHARMACIES

9.3 RETAIL PHARMACIES

9.4 WEIGHT MANAGEMENT CLINICS

9.5 HOSPITAL PHARMACIES

9.6 WELLNESS & FITNESS CENTERS

10 EUROPE OBESITY TREATMENT MARKET, BY PATIENT TYPE

10.1 OVERVIEW

10.2 CLASS III

10.3 CLASS II

10.4 CLASS I

11 EUROPE OBESITY TREATMENT MARKET, BY REGION

11.1 EUROPE

11.1.1 UNITED KINGDOM

11.1.2 GERMANY

11.1.3 FRANCE

11.1.4 ITALY

11.1.5 SPAIN

11.1.6 RUSSIA

11.1.7 TURKEY

11.1.8 NETHERLANDS

11.1.9 SWITZERLAND

11.1.10 POLAND

11.1.11 IRELAND

11.1.12 AUSTRIA

11.1.13 NORWAY

11.1.14 REST OF EUROPE

12 EUROPE OBESITY TREATMENT MARKET, COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: EUROPE

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 NOVO NORDISK A/S

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENT

14.2 ELI LILLY AND COMPANY

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENT/NEWS

14.3 MEDTRONIC

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENT

14.4 BOSTON SCIENTIFIC CORPORATION

14.4.1 COMPANY SNAPSHOTS

14.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.5 JOHNSON & JOHNSON SERVICES, INC.

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENT/NEWS

14.6 ALTIMMUNE

14.6.1 COMPANY SNAPSHOT

14.6.2 PIPELINE PORTFOLIO

14.6.3 RECENT UPDATES

14.7 ASTRAZENECA

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENT/NEWS

14.8 ALLURION

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

1.1.5 RECENT DEVELOPMENT/NEWS 262

14.9 AMGEN

14.9.1 COMPANY SNAPSHOT

14.9.2 REVENUE ANALYSIS

14.9.3 PRODUCT PORTFOLIO

1.1.13 RECENT DEVELOPMENT/NEWS 267

14.1 ARENA PHARMACEUTICALS LTD

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENT

14.11 CURRAX PHARMACEUTICALS LLC

14.11.1 COMPANY SNAPSHOT

14.11.2 PRODUCT PORTFOLIO

14.11.3 RECENT DEVELOPMENT

14.12 COUSIN SURGERY

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENT

14.13 F. HOFFMANN-LA ROCHE LTD

14.13.1 COMPANY SNAPSHOT

14.13.2 REVENUE ANALYSIS

14.13.3 PRODUCT PORTFOLIO

14.13.4 RECENT DEVELOPMENT/NEWS

14.14 FITTERFLY HEALTHTECH PVT. LTD.

14.14.1 COMPANY SNAPSHOT

14.14.2 PRODUCT PORTFOLIO

14.14.3 RECENT DEVELOPMENT

14.15 MORPHIC MEDICAL, INC

14.15.1 COMPANY SNAPSHOT

14.15.2 PRODUCT PORTFOLIO

14.15.3 RECENT DEVELOPMENT

14.16 NOOM, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENT

14.17 OMADA HEALTH INC

14.17.1 COMPANY SNAPSHOT

14.17.2 PRODUCT PORTFOLIO

14.17.3 RECENT DEVELOPMENT

14.18 RESHAPE LIFESCIENCES

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

1.1.7 RECENT DEVELOPMENT/NEWS 286

14.19 RAZIEL

14.19.1 COMPANY SNAPSHOT

14.19.2 PRODUCT PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.2 SPATZ FGIA INC.

14.20.1 COMPANY SNAPSHOT

14.20.2 PRODUCT PORTFOLIO

14.20.3 RECENT DEVELOPMENT

14.21 SANOFI

14.21.1 COMPANY SNAPSHOT

14.21.2 REVENUE ANALYSIS

14.21.3 PRODUCT PORTFOLIO

14.21.4 RECENT DEVELOPMENT

14.22 SANIONA

14.22.1 COMPANY SNAPSHOT

14.22.2 REVENUE ANALYSIS

14.22.3 PRODUCT PORTFOLIO

14.22.4 RECENT DEVELOPMENT

14.23 USGI MEDICAL

14.23.1 COMPANY SNAPSHOT

14.23.2 PRODUCT PORTFOLIO

14.23.3 RECENT DEVELOPMENT

14.24 VIVUS LLC.

14.24.1 COMPANY SNAPSHOT

14.24.2 PRODUCT PORTFOLIO

14.24.3 RECENT DEVELOPMENT/NEWS

14.25 VIKING THERAPEUTICS

14.25.1 COMPANY SNAPSHOTS

14.25.2 REVENUE ANALYSIS

14.25.3 PRODUCT PORTFOLIO

14.25.4 RECENT DEVELOPMENT

14.26 ZEALAND PHARMA

14.26.1 COMPANY SNAPSHOT

14.26.2 REVENUE ANALYSIS

14.26.3 PRODUCT PORTFOLIO

14.26.4 RECENT DEVELOPMENT/NEWS

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

TABLE 1 OBESITY PREVALENCE BY REGION (ADULTS)

TABLE 2 OBESITY PREVALENCE BY GENDER (ADULTS)

TABLE 3 OBESITY PREVALENCE BY AGE (ADULTS)

TABLE 4 EUROPE CLINICAL TRIAL MARKET FOR OBESITY TREATMENT

TABLE 5 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE EUROPE OBESITY TREATMENT MARKET

TABLE 6 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE EUROPE OBESITY TREATMENT MARKET

TABLE 7 EUROPE OBESITY STATISTICS (2022)

TABLE 8 EUROPE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 9 EUROPE PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 10 EUROPE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 11 EUROPE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 12 EUROPE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 13 EUROPE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 EUROPE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 15 EUROPE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 16 EUROPE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 17 EUROPE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 18 EUROPE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 19 EUROPE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 20 EUROPE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 EUROPE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 22 EUROPE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 23 EUROPE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 24 EUROPE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 25 EUROPE ADULT OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 26 EUROPE GERIATRIC OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 27 EUROPE PEDIATRIC OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 28 EUROPE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 29 EUROPE ONLINE PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 30 EUROPE RETAIL PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 31 EUROPE WEIGHT MANAGEMENT CLINICS IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 32 EUROPE HOSPITAL PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 33 EUROPE WELLNESS & FITNESS CENTERS IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 34 EUROPE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 EUROPE CLASS III IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 36 EUROPE CLASS II IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 37 EUROPE CLASS I IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 38 EUROPE OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 39 EUROPE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 40 EUROPE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 41 EUROPE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 42 EUROPE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 43 EUROPE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 44 EUROPE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 45 EUROPE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 46 EUROPE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 47 EUROPE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 48 EUROPE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 49 EUROPE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 50 EUROPE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 51 EUROPE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 52 EUROPE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 53 UNITED KINGDOM OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 54 UNITED KINGDOM PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 55 UNITED KINGDOM CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 56 UNITED KINGDOM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 57 UNITED KINGDOM RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 58 UNITED KINGDOM COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 59 UNITED KINGDOM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 60 UNITED KINGDOM BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 61 UNITED KINGDOM NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 62 UNITED KINGDOM INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 63 UNITED KINGDOM MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 64 UNITED KINGDOM OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 65 UNITED KINGDOM OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 66 UNITED KINGDOM OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 GERMANY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 68 GERMANY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 69 GERMANY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 70 GERMANY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 71 GERMANY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 72 GERMANY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 73 GERMANY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 74 GERMANY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 75 GERMANY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 76 GERMANY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 GERMANY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 78 GERMANY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 79 GERMANY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 80 GERMANY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 81 FRANCE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 FRANCE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 83 FRANCE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 84 FRANCE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 85 FRANCE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 86 FRANCE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 87 FRANCE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 88 FRANCE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 89 FRANCE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 90 FRANCE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 91 FRANCE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 92 FRANCE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 93 FRANCE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 94 FRANCE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 95 ITALY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 96 ITALY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 97 ITALY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 98 ITALY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 99 ITALY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 100 ITALY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 101 ITALY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 102 ITALY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 103 ITALY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 104 ITALY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 105 ITALY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 106 ITALY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 107 ITALY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 108 ITALY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 SPAIN OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 110 SPAIN PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 SPAIN CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 112 SPAIN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 113 SPAIN RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 114 SPAIN COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 115 SPAIN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 116 SPAIN BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 117 SPAIN NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 118 SPAIN INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 SPAIN MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 SPAIN OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 121 SPAIN OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 122 SPAIN OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 RUSSIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 124 RUSSIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 RUSSIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 RUSSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 RUSSIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 128 RUSSIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 129 RUSSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 130 RUSSIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 131 RUSSIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 RUSSIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 133 RUSSIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 134 RUSSIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 135 RUSSIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 136 RUSSIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 TURKEY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 138 TURKEY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 139 TURKEY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 TURKEY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 141 TURKEY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 142 TURKEY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 143 TURKEY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 144 TURKEY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 145 TURKEY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 146 TURKEY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 147 TURKEY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 148 TURKEY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 149 TURKEY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 150 TURKEY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 NETHERLANDS OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 NETHERLANDS PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 153 NETHERLANDS CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 NETHERLANDS BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 NETHERLANDS RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 156 NETHERLANDS COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 157 NETHERLANDS BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 158 NETHERLANDS BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 NETHERLANDS NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 160 NETHERLANDS INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 NETHERLANDS MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 162 NETHERLANDS OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 163 NETHERLANDS OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 164 NETHERLANDS OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 SWITZERLAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 166 SWITZERLAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 SWITZERLAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 168 SWITZERLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 SWITZERLAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 SWITZERLAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 171 SWITZERLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 172 SWITZERLAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 173 SWITZERLAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 174 SWITZERLAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 SWITZERLAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 176 SWITZERLAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 177 SWITZERLAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 178 SWITZERLAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 POLAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 180 POLAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 181 POLAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 POLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 183 POLAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 184 POLAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 185 POLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 186 POLAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 187 POLAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 188 POLAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 189 POLAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 POLAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 191 POLAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 192 POLAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 193 IRELAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 194 IRELAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 195 IRELAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 IRELAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 197 IRELAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 198 IRELAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 199 IRELAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 200 IRELAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 IRELAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 IRELAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 203 IRELAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 204 IRELAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 205 IRELAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 206 IRELAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 207 AUSTRIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 AUSTRIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 209 AUSTRIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 210 AUSTRIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 AUSTRIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 AUSTRIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 213 AUSTRIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 214 AUSTRIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 AUSTRIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216 AUSTRIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 AUSTRIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 218 AUSTRIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 219 AUSTRIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 220 AUSTRIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 221 NORWAY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 222 NORWAY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 NORWAY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 224 NORWAY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 NORWAY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 NORWAY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 227 NORWAY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 228 NORWAY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 NORWAY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 230 NORWAY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 231 NORWAY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 NORWAY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 233 NORWAY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 234 NORWAY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 235 REST OF EUROPE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

List of Figure

FIGURE 1 EUROPE OBESITY TREATMENT MARKET: SEGMENTATION

FIGURE 2 EUROPE OBESITY TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE OBESITY TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 EUROPE OBESITY TREATMENT MARKET: REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE OBESITY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE OBESITY TREATMENT MARKET: LIFELINE CURVE

FIGURE 7 EUROPE OBESITY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE OBESITY TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE OBESITY TREATMENT MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 EUROPE OBESITY TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 EUROPE OBESITY TREATMENT MARKET: SEGMENTATION

FIGURE 12 EUROPE OBESITY TREATMENT MARKET EXECUTIVE SUMMARY

FIGURE 13 STRATEGIC DECISIONS

FIGURE 14 FIVE SEGMENTS COMPRISE THE EUROPE OBESITY TREATMENT MARKET , BY TREATMENT TYPE

FIGURE 15 RISING PREVALENCE OF OBESITY IS EXPECTED TO DRIVE THE GROWTH OF EUROPE OBESITY TREATMENT MARKET FROM 2025 TO 2032

FIGURE 16 THE PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE OBESITY TREATMENT MARKET IN 2025 - 2032

FIGURE 17 MARKET OVERVIEW

FIGURE 18 PREVALENCE OF OBESITY IN ADULTS AGE 20 AND OLDER, BY SEX AND AGE: UNITED STATES, AUGUST 2021–AUGUST 2023 SOURCE: CENTERS FOR DISEASE CONTROL AND PREVENTION.

FIGURE 19 SHARE OF PRE-OBESE AND OBESE PERSONS AGED 16 YEARS OR OVER, BY SEX, 2022 (%)

FIGURE 20 EUROPE OBESITY TREATMENT MARKET: BY TREATMENT TYPE, 2024

FIGURE 21 EUROPE OBESITY TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)

FIGURE 22 EUROPE OBESITY TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)

FIGURE 23 EUROPE OBESITY TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 24 EUROPE OBESITY TREATMENT MARKET: BY AGE GROUP, 2024

FIGURE 25 EUROPE OBESITY TREATMENT MARKET: BY AGE GROUP, 2025-2032 (USD THOUSAND)

FIGURE 26 EUROPE OBESITY TREATMENT MARKET: BY AGE GROUP, CAGR (2025-2032)

FIGURE 27 EUROPE OBESITY TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 28 EUROPE OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 29 EUROPE OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)

FIGURE 30 EUROPE OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)

FIGURE 31 EUROPE OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 32 EUROPE OBESITY TREATMENT MARKET: BY PATIENT TYPE, 2024

FIGURE 33 EUROPE OBESITY TREATMENT MARKET: BY PATIENT TYPE, 2025-2032 (USD THOUSAND)

FIGURE 34 EUROPE OBESITY TREATMENT MARKET: BY PATIENT TYPE, CAGR (2025-2032)

FIGURE 35 EUROPE OBESITY TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 36 EUROPE OBESITY TREATMENT MARKET: SNAPSHOT (2024)

FIGURE 37 EUROPE OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Industry Related Reports

Browse Related Pages

Testimonial
Claudio Rondena Group Business Development & Strategic Marketing Director,
C.O.C Farmaceutici SRL
"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future
Request for TOC Speak to Analyst Free Sample Report Inquire Before Buy Now
Request a Call
Please select country
Please enter Contact No.
Please enter job tital
Please enter company name
Request for Demo
Please select country
Please enter Contact No.
Please enter job tital
Please enter company name
Office Number 402, Amanora
Chambers, Magarpatta Road, Hadapsar
Pune – 411028.

Reports

Market Insights

Support

Solutions

DMCA Protected © DataBridge - All Rights Reserved.

We Accept Payment